OPK earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -4.29. Updated 2026-07-23.
OPKO Health (OPK) Research Hub
OPKO Health (OPK) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.57 USD (+1.95%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.29, market cap 0.90B. This hub links to the full technical, earnings and options research available for OPK.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.57 USD (+1.95%) |
| 52-week range | 1.17 USD – 1.73 USD |
| Trend regime | Range |
| 14-day RSI | 68.5 (Bullish) |
| Trailing P/E | -4.29 |
| Market cap | 0.90B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for OPK
Covered Call on OPK: how it works, illustrative setup around the real 1.57 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on OPK: how it works, illustrative setup around the real 1.57 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on OPK: how it works, illustrative setup around the real 1.57 USD price, max profit/loss, breakeven and when to use it. Educational.
OPK technical analysis: range, last 1.57 USD, RSI 68.5, 52w range 1.17 USD–1.73 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is OPK in?
OPKO Health (OPK) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is OPK in an uptrend or downtrend?
As of 2026-09-11, OPK is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is OPK's trailing P/E ratio?
OPK's trailing P/E is -4.29, with a market cap of 0.90B. See the earnings research page for full valuation detail.
When does OPK next report earnings?
OPK is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -0.08 USD.